Some Quick Facts About Eli Lilly and Company (LLY)

Eli Lilly and Company moved -2.3% this afternoon session, trading between a high of $537.29 and a low of $516.57 per share. Yesterday the stock finished at $538.29 per share, compared to an average analyst target price of $574.9.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The large-cap biotechnology: pharmaceutical preparations company is based in the United States, and over the last twelve months it has returned a dividend yield of 0.8%. Eli Lilly and Company has trailing twelve months earnings per share (EPS) of 7.2, which at today's prices amounts to a price to earnings (P/E) ratio of 73.1.

Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of 2.26. Usually a PEG ratio between 0 and 1 indicates a potentially undervalued company.

Overview of the Company's Gross Margins:

Date Reported Revenue ($ k) Cost of Revenue ($ k) Gross Margins (%) YoY Growth (%)
2023-02-22 28,541,400 -6,629,800 77 4.05
2022-02-23 28,318,400 -7,312,800 74 -5.13
2021-02-17 24,539,800 -5,483,300 78 -1.27
2020-02-19 22,319,500 -4,721,200 79 1.28
2019-02-19 21,493,300 -4,681,700 78 6.85
2018-02-20 22,871,300 -6,150,800 73

At 76.5%, Eli Lilly and Company's average gross margins are wider than the 60.94% average of its industry peer group, which suggests that the firm might have a competitive advantage.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.